Description: Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Home Page: www.aileronrx.com
ALRN Technical Analysis
285 Summer Street
Boston,
MA
02210
United States
Phone:
617 995 0900
Officers
| Name | Title |
|---|---|
| Dr. Manuel C. Aivado M.D., Ph.D. | Pres, CEO & Director |
| Ms. Susan L. Drexler CPA, M.B.A. | Interim CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. D. Allen Annis Ph.D. | Sr. VP of Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5022 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-06-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |